Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The World’s First (Official) Biosimilar Antibody Goes to… Rheumatoid Arthritis

Published: Wednesday, August 08, 2012
Last Updated: Wednesday, August 08, 2012
Bookmark and Share
Celltrion announces the approval of Remsima (CT-P13), a biosimilar antibody, by the Korean Food and Drug Administration.

The end of July 2012 proved exciting for the world of biosimilar manufacturers. However, for the regulatory officials worldwide it meant more uncertainty and unknowns about proper, global biosimilar guidelines.

On July 23, 2012, South Korean biosimilar manufacturer Celltrion announced the approval of Remsima (CT-P13), a biosimilar antibody, by the Korean Food and Drug Administration. Remsima is a biosimilar version of Johnson & Johnson’s Remicade (infliximab) which was one of the first monoclonal antibody TNF inhibitors approved for the treatment of Rheumatoid Arthritis (RA). Remsima is approved for several indications and will be marketed in Asia and South America by the end of the year. In Europe, Celltrion filed for market authorization with partner Hospira to launch Remsima under the name of Infectra. Interestingly, Remsima is only the first officially approved biosimilar antibody for RA therapy as Reditux, a MabThera biosimilar, was launched in India in 2007, but under unapproved biosimilar development guidelines. The first-ever approved biosimilar, Omnitrope (somatropin), arrived on the European market in 2006. Since then 14 more drugs across the drug classes of human growth hormone, granulocyte stimulating factor, and erythropoietin have been approved in the European Union (EU).

The definition of a biosimilar drug according to the World Health Organization is as follows: a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product. This definition seems straightforward, but guidelines to maintain the safety and efficacy of these drugs have been difficult to draft and approve worldwide. The issues which have come under scrutiny include questioning of the biosimilar formulation, the amount of clinical trial data needed, and quality control of manufacturing practices. Without a global resolve and understanding of the clinical and regulatory factors involved in designing and marketing a biosimilar drug, the market uptake will likely be slow.

With several antibodies coming off patent in the next few years, biosimilars will be waiting in the wings to take some revenue, but they are not likely to cannibalize the market due to the uncertainties which have been in question. Even though the biosimilar market earned about $170m in 2010, uptake will be slow compared to generics for reasons stated, while considerable investment is also needed to produce a biosimilar and bring it to market. In order for biosimilars to become competitive, price reduction strategies could likely grab the attention from consumers, physicians, and payers, which could increase the biosimilar market share. However, due to high manufacturing costs, biosimilar drugs are less likely to be included in discount offerings which generic drugs are accustomed to.

Since the upcoming biosimilars are from different drug classes than those currently on the market, there will be supply and demand drivers. Companies will be trying to get the leg-up on cost-saving strategies and maximize their potential to lead in quality assurance of the production of biosimilars. Pharmaceutical and generic manufacturers are entering this arena, and some are being guided by Contract Research Organizations (CROs) to aid in market strategy specific to biosimilars. Big Pharma companies such as Amgen, Biogen Idec, and Merck are competing with well-known generics companies which include Hospira, Teva, and Watson. The CRO guidance is coming from familiar organizations such as Biocon, Harvest Moon, and Quintiles. Other potential players looking for a piece of the biosimilar pie include Astra Zeneca, Fujifilm, and GE Healthcare.

In 2011, the US was responsible for 36% of the worldwide biologic drug sales, while the five major European markets collectively took second with 22%. Currently, it is estimated that the biosimilar market will reach close to $4 billion by 2017. The US is lagging behind with legislation and regulations for the approval and marketing of biosimilars as compared to the EU, Japan, and numerous other developed countries that have had terms in place for several years. GlobalData believes that, if the US healthcare system and US FDA are unable to design and approve regulatory guidelines for biosimilar drugs within the next few years, the US healthcare system will lose more money, and be forced to pay for more expensive brands.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promising Malaria and Dengue Vaccines Will Not Defeat Diseases
Although vaccination is a key part of the control of disease GlobalData stress the importance of a multi-dimensional approach.
Friday, May 22, 2015
Pfizer Contemplates $2 Billion Acquisition of Strides’ Agila Unit
As drug makers continue to jostle for market share and deal with declining revenues from their off-patent blockbuster drugs, M&A activity is showing no indication of slowing down in 2013.
Thursday, January 17, 2013
Heavyweight Battle: Buyer-Versus-Supplier Showdown in Childhood Vaccines
Federal judge moves forward with meningococcal vaccine antitrust suit against Sanofi.
Tuesday, August 21, 2012
The World’s First (Official) Biosimilar Antibody Goes to… Rheumatoid Arthritis
Remsima is the first officially approved biosimilar antibody for RA therapy.
Thursday, August 09, 2012
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Enumeral, MD Anderson Enter Into Collaboration
Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
Joint venture for GlycoMar Limited and MicroA AS
Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!